ACT Genomics

Executive Summary

ACT Genomics is a Taiwan-based precision oncology diagnostics company that provides next-generation sequencing (NGS)-based genomic profiling for cancer patients and clinicians. Leveraging its in-house bioinformatics platform and FDA-cleared IVD assays, the company delivers actionable biomarker insights to guide targeted therapy, immunotherapy, and clinical trial enrollment across solid tumors. Serving hospitals, physicians, and biopharma partners throughout Asia, ACT Genomics has established itself as a key player in the region's precision oncology market. Founded in 2014 and now in the commercial stage with 200-500 employees, the company continues to expand its test menu and geographic reach. ACT Genomics is well-positioned to capitalize on the growing demand for genomic testing in Asia, driven by increasing cancer incidence and adoption of precision medicine. While the company is private and does not disclose financials, its commercial traction and partnerships suggest a solid foundation. Key catalysts include the launch of a comprehensive liquid biopsy assay to capture the non-invasive testing market, expansion of its IVD portfolio into new Asian markets, and potential collaborations with pharmaceutical companies for companion diagnostic development. The company's FDA clearance provides a regulatory advantage, and its focus on Asia offers a large addressable market. However, competition from established players and pricing pressures remain risks.

Upcoming Catalysts (preview)

• Q2 2026Launch of comprehensive liquid biopsy assay for multi-cancer detection70% success
• Q4 2026Regulatory approval for expanded IVD panel in additional Asian countries (e.g., Japan, South Korea)60% success
• Q3 2026Announcement of a pharma partnership for companion diagnostic development50% success